EOFLOW Co.,Ltd. (KOSDAQ: 294090)
South Korea
· Delayed Price · Currency is KRW 3,460.00
-180.00 (-4.95%)
Dec 20, 2024, 9:00 AM KST
-19.53% (1Y)
| Market Cap | 105.31B |
| Revenue (ttm) | 6.28B |
| Net Income (ttm) | -63.33B |
| Shares Out | 30.44M |
| EPS (ttm) | -2,081.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,264,512 |
| Open | 3,630.00 |
| Previous Close | 3,640.00 |
| Day's Range | 3,315.00 - 3,635.00 |
| 52-Week Range | 2,690.00 - 18,500.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 20, 2025 |
About EOFLOW Co.,Ltd.
EOFLOW Co.,Ltd. develops and provides drug delivery solutions. The company offers EOPatch, a wearable insulin pump system. EOFLOW Co.,Ltd. was founded in 2011 and is based in Seongnam, South Korea. [Read more]
Industry Surgical and Medical Instruments and Apparatus
Founded 2011
Employees 106
Stock Exchange KOSDAQ
Ticker Symbol 294090
Financial Performance
In 2023, EOFLOW Co.,Ltd.'s revenue was 6.59 billion, a decrease of -1.77% compared to the previous year's 6.71 billion. Losses were -61.94 billion, 101.7% more than in 2022.
Financial StatementsNews
Insulet awarded $452M in damages in EOFlow case
Insulet (PODD) wins $452M in trade secrets case against EOFlow Co., awarded $170M compensatory and $282M exemplary damages.
16 days ago - Seeking Alpha